{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:34:34Z","timestamp":1767893674323,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effectiveness and safety of damoctocog alfa pegol in patients with severe and nonsevere hemophilia A in the fifth interim analysis of the ongoing HEM\u2010POWR study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HEM\u2010POWR (NCT03932201) is a multinational, Phase 4, prospective observational study. The key objectives were the annualized bleeding rate (ABR) and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At data cutoff (July 8, 2024), the safety analysis set and full analysis set (FAS) included 370 and 270 patients, respectively. In the modified FAS (patients with \u2265\u200990\u2009days of bleed data), the mean (standard deviation; SD) ABR for total bleeds was 2.8 (5.9) 12\u2009months prior to damoctocog alfa pegol initiation with the previous FVIII product and 2.1 (4.8) during the observation period. Bleed protection with damoctocog alfa pegol was maintained across disease severity, age group, BMI group, dosing regimen, and patient inhibitor history. One patient died due to spinal cord ischemia unrelated to the study drug. One patient developed a transient low\u2010titer inhibitor, which resolved without clinical consequence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This updated analysis further demonstrated the effectiveness, acceptable safety profile, and tolerability of damoctocog alfa pegol for previously treated patients with severe and nonsevere hemophilia A from adolescence to older age in a real\u2010world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70026","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:57:42Z","timestamp":1761127062000},"page":"148-159","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing\n                    <scp>HEM<\/scp>\n                    \u2010\n                    <scp>POWR<\/scp>\n                    Study"],"prefix":"10.1111","volume":"116","author":[{"given":"Mark T.","family":"Reding","sequence":"first","affiliation":[{"name":"Center for Bleeding and Clotting Disorders University of Minnesota Medical Center  Minneapolis Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Alvarez Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Thrombosis and Haemostasis Unit Hospital Universitario La Paz  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"Department of Oncology, Center for Bleeding Disorders and Coagulation Careggi University Hospital  Florence Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maissaa","family":"Janbain","sequence":"additional","affiliation":[{"name":"Deming Department of Internal Medicine, Section of Hematology and Medical Oncology Tulane School of Medicine  New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine Nagoya University Hospital  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[{"name":"Department of Hematology University Medical Center Groningen  Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Schmidt","sequence":"additional","affiliation":[{"name":"OS Operations Bayer  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Hematology and Transfusion Medicine University Hospital Bonn, Medical Faculty, University of Bonn  Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(11)61139\u20102"},{"key":"e_1_2_10_3_1","volume-title":"In: StatPearls","author":"Salen P.","year":"2024"},{"key":"e_1_2_10_4_1","unstructured":"National Organization for Rare Disorders \u201cHemophilia A \u201daccessed July 15 2024 https:\/\/rarediseases.org\/rare\u2010diseases\/hemophilia\u2010a\/."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1208"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100047"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15076"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2450\/2017.0150\u201017"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14168"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14691"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102015.1.41"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2019.2018.0393"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-023-00550-6"},{"issue":"3","key":"e_1_2_10_15_1","first-page":"361","article-title":"The Management of Hemophilia in Elderly Patients","volume":"2","author":"Franchini M.","year":"2007","journal-title":"Clinical Interventions in Aging"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13616"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13963"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102009\u201011\u2010254755"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010019\u201001190\u20101"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13597"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14297"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13853"},{"key":"e_1_2_10_23_1","unstructured":"European Medicines Agency \u201cJivi Sumary of Product Characteristics \u201daccessed July 15 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/jivi\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_24_1","unstructured":"Food and Drug Administration \u201cJivi Prescribing Information \u201daccessed July 15 2024 https:\/\/www.fda.gov\/files\/vaccines %20blood%20%26%20biologics\/published\/Package\u2010Insert\u2010JIVI.pdf."},{"key":"e_1_2_10_25_1","unstructured":"Australian Government \u201cJivi Prescribing Information \u201daccessed July 15 2024 https:\/\/www.tga.gov.au\/sites\/default\/files\/2023\u201011\/auspar\u2010jivi\u2010231109\u2010pi.pdf."},{"key":"e_1_2_10_26_1","unstructured":"PMDA \u201cJivi Prescribing Information \u201daccessed July 15 2024 https:\/\/www.pmda.go.jp\/files\/000229786.pdf."},{"key":"e_1_2_10_27_1","unstructured":"Government of Canada \u201cJivi Product Monograph \u201daccessed July 15 2024 https:\/\/pdf.hres.ca\/dpd_pm\/00071927.PDF."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12506"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14167"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13291"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15723"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14114"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102020\u2010044997"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100912"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100890"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-019-00374-x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100852"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:10:12Z","timestamp":1767874212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/ejh.70026"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70026","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"2025-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}